CoChat

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

Open access
Kummar, Shivaani, Gutierrez, Martin E., Gardner, Erin R., Chen, Xiaohong, Figg, William D., Zajac-Kaye, Maria, Chen, Min, Steinberg, Seth M., Muir, Christine A., Yancey, Mary Ann, Horneffer, Yvonne R., Juwara, Lamin, Melillo, Giovanni, Ivy, S. Percy, Merino, Maria, Neckers, Len, Steeg, Patricia S., Conley, Barbara A., Giaccone, Giuseppe, Doroshow, James H., Murgo, Anthony J. · 2010 · European Journal of Cancer
Cited by 122

The DOI matches its Crossref record.

Abstract

Purpose Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, administered on a twice weekly schedule in patients with advanced cancer. Experimental Design 17-DMAG was administered as a 1- to 2-h infusion twice weekly in 4-week cycles. An accelerated titration design was followed until toxicity was observed, at which point standard dose escalation proceeded. MTD was defined as the dose at which no more than one of six patients experienced a dose-limiting toxicity (DLT). Pharmacokinetics were assessed, and Hsp70 mRNA, whose gene product is a chaperone previously shown to be upregulated following inhibition of Hsp90, was measured in peripheral blood mononuclear cells (PBMCs). Results A total of 31 patients received 92 courses of treatment. The MTD was 21 mg/m2/d; 20 patients were enrolled at this dose level. Nine patients had stable disease for a median of 4 (range 2-22) months. Both Cmax and AUC increased proportionally with dose. The most common toxicities were grade 1 or 2 fatigue, anorexia, nausea, blurred vision, and musculoskeletal pain. DLTs were peripheral neuropathy and renal dysfunction. Expression of Hsp70 mRNA in PBMCs was highly variable. Conclusion Twice-weekly i.v. infusion of 17-DMAG is well tolerated, and combination phase I studies are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2009.10.026

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 122

Metadata

Authors
Kummar, S., Gutierrez, M. E., Gardner, E. R., Chen, X., Figg, W. D., Zajac-Kaye, M., Chen, M., Steinberg, S. M., Muir, C. A., Yancey, M. A., Horneffer, Y. R., Juwara, L., Melillo, G., Ivy, S. P., Merino, M., Neckers, L., Steeg, P. S., Conley, B. A., Giaccone, G., Doroshow, J. H., & Murgo, A. J.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2010-01
Volume
46
Issue
2
Pages
340-347
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2108502796
Cited by
122
References
0
FWCI
3.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. https://app.cochat.ai/papers/10.1016/j.ejca.2009.10.026
The paper
Kummar, S., Gutierrez, M. E., Gardner, E. R., Chen, X., Figg, W. D., Zajac-Kaye, M., Chen, M., Steinberg, S. M., Muir, C. A., Yancey, M. A., Horneffer, Y. R., Juwara, L., Melillo, G., Ivy, S. P., Merino, M., Neckers, L., Steeg, P. S., Conley, B. A., Giaccone, G., . . . Murgo, A. J. (2010). Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2009.10.026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.